https://www.selleckchem.com/pr....oducts/fluorofurimaz
71) and calibration across observed and predicted tertiles of risk. New-onset AF events rates increased steeply by increasing tertiles of the risk-score. Compared to tertile 1, the risk of new-onset AF was 2.5-fold higher in tertile 2, and 6.3-fold higher in tertile 3. Rivaroxaban had no effect in reducing new-onset AF. In time-updated models, new-onset AF was associated with a higher risk of subsequent all-cause death HR (95%CI) 1.38 (1.11-1.73). A well-calibrated risk-score identified patients at risk of new-onset AF in the C
Like
Comment
Share
